

Supplementary Table 4. Baseline characteristics of subgroup with two tumors and PS-matched cohorts for overall survival (PS cohort 1) and recurrence-free survival (PS cohort 2)

Variables	Entire patients			PS-matched cohort 1			PS-matched cohort 2			
	Total (n=349)	LR (n=87)	TACE (n=262)	P-value	LR (n=70)	TACE (n=118)	P-value	LR (n=65)	TACE (n=90)	P-value
Demographic characteristics										
Age (years)	67 (62-73)	67 (61-72)	68 (62-73)	0.13	67 (61-72)	67 (63-73)	0.58	67 (61-71)	67 (61-71)	0.76
Male	294 (84.2)	76 (87.4)	218 (83.2)	0.45	63 (90.0)	97 (82.2)	0.22	58 (89.2)	79 (87.8)	0.98
Body mass index (kg/m ²)	24.4 (22.6-26.5)	24.1 (22.4-26.0)	24.5 (22.8-26.6)	0.29	24.2 (22.2-26.3)	24.3 (22.7-25.9)	0.76	24.3 (22.4-26.6)	24.3 (22.9-26.3)	0.85
Diabetes mellitus*	86 (24.6)	23 (26.4)	63 (24.0)	0.80	18 (25.7)	33 (38.0)	0.87	15 (23.1)	20 (22.2)	0.99
Hypertension†	100 (28.7)	26 (29.9)	74 (28.2)	0.88	22 (31.4)	33 (28.0)	0.74	16 (24.6)	24 (26.7)	0.92
Alcohol										
None	95 (27.3)	22 (25.4)	73 (27.9)		19 (27.2)	40 (33.9)		18 (27.7)	24 (26.7)	
Past drinker	53 (15.2)	11 (12.6)	42 (16.0)	0.68	8 (11.4)	16 (13.6)	0.39	6 (9.2)	11 (12.2)	0.84
Current drinker	123 (35.2)	31 (35.6)	92 (35.1)		24 (34.3)	42 (35.6)		24 (36.9)	36 (40.0)	
Missing values	78 (22.3)	23 (26.4)	55 (21.0)		19 (27.1)	20 (16.9)		17 (26.2)	19 (21.1)	
Ascites										
None	321 (92.0)	85 (97.7)	236 (90.1)	0.06	68 (97.1)	115 (97.5)	0.99	63 (96.9)	89 (98.9)	0.78
Mild	18 (5.1)	2 (2.3)	16 (6.1)		2 (2.9)	3 (2.5)		2 (3.1)	1 (1.1)	
Moderate to severe	10 (2.9)	0 (0.0)	10 (3.8)		-	-		-	-	
ALBI score	-2.0 (-2.3 to -1.8)	-2.2 (-2.4 to 2.0)	-1.9 (-2.2 to 1.7)	<0.001	-	-		-	-	
ALBI grade										
Grade 1/2	311 (89.1)	87 (100.0)	224 (85.5)	<0.001	-	-		-	-	
Grade 3	38 (10.9)	0 (0.0)	38 (14.5)		-	-		-	-	
Laboratory findings										
Platelets (<1,000/mm ³)	107 (82-131)	126 (106-140)	99 (75-125)	<0.001	125 (102-137)	119 (96-134)	0.18	124 (102-137)	120 (93-136)	0.47
AST (IU/L)	37 (28-52)	33 (26-46)	38 (29-54)	0.01	34 (26-45)	33 (27-46)	0.89	34 (26-45)	35 (28-48)	0.77
ALT (IU/L)	31 (21-46)	33 (22-43)	31 (21-46)	0.69	33 (22-48)	31 (22-45)	0.71	33 (23-48)	33 (22-47)	0.79
ALP (IU/L)	83 (66-108)	68 (58-87)	86 (72-113)	<0.001	69.0 (59.0-87.0)	76.0 (65.0-87.0)	0.13	68.0 (59.0-87.0)	73.0 (63.0-86.0)	0.41
Albumin (g/dL)	3.8 (3.6-4.0)	4.0 (3.7-4.2)	3.7 (3.5-4.0)	<0.001	3.9 (3.7-4.2)	3.9 (3.7-4.1)	0.67	3.9 (3.7-4.2)	3.8 (3.6-4.1)	0.53
Total bilirubin (mg/dL)	0.9 (0.7-1.3)	0.7 (0.6-1.0)	1.0 (0.7-1.4)	<0.001	0.7 (0.6-1.0)	0.8 (0.6-1.0)	0.69	0.7 (0.5-1.0)	0.7 (0.6-1.0)	0.92
Total cholesterol (mg/dL)	152 (133-178)	161 (141-185)	148 (131-177)	0.01	158 (138-183)	165 (138-185)	0.54	159 (141-178)	166 (138-188)	0.56
Creatinine (mg/dL)	0.8 (0.7-0.9)	0.8 (0.8-0.9)	0.8 (0.7-0.9)	0.42	0.8 (0.8-1.0)	0.9 (0.8-0.9)	0.69	0.8 (0.8-0.9)	0.8 (0.7-0.9)	0.52
PT (INR)	1.1 (1.0-1.2)	1.0 (1.0-1.1)	1.1 (1.1-1.2)	<0.001	1.1 (1.0-1.1)	1.1 (1.0-1.1)	0.94	1.1 (1.0-1.1)	1.1 (1.0-1.1)	0.98
AFP (ng/mL)	12.5 (5.6-61.3)	18.7 (5.5-61.3)	11.6 (5.6-63.0)	0.38	18.7 (5.2-56.5)	11.6 (5.1-89.1)	0.71	18.8 (6.3-56.5)	10.2 (5.2-140.2)	0.58

Supplementary Table 4. Continued

Variables	Entire patients			PS-matched cohort 1			PS-matched cohort 2			
	Total (n=349)	LR (n=87)	TACE (n=262)	P-value	LR (n=70)	TACE (n=118)	P-value	LR (n=65)	TACE (n=90)	P-value
Tumor characteristics										
Size of tumor (cm)	2.0 (1.5-2.5)	2.1 (1.7-2.6)	2.0 (1.5-2.5)	0.01	2.0 (1.7-2.5)	2.0 (1.5-2.5)	0.62	2.0 (1.6-2.5)	2 (1.5-2.5)	0.42

Values are presented as number (%) or median (interquartile range).

PS, propensity score; LR, liver resection; TACE, transarterial chemoembolization; ALBI, albumin-bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; PT, prothrombin time; INR, international-normalized-ratio; AFP, alpha-fetoprotein.

*A total of Seven patients had missing values of diabetes mellitus in the entire cohort (six and one patients in the TACE and LR groups, respectively); †A total of eight patients had missing values of hypertension in the entire cohort (six and two patients in the TACE and LR groups, respectively).